Eikon Therapeutics (EIKN) Stock Price, News & Analysis

Company Overview

Eikon Therapeutics, Inc. is a biotechnology company focused on discovering and developing medicines by combining advanced live-cell imaging with drug discovery and development. The company’s platform is designed to track individual molecules and cellular processes in real time, providing researchers with detailed insight into how potential therapies work inside living cells.

Eikon applies this technology primarily to the development of treatments for serious diseases, including cancer and other conditions involving complex biological pathways. Its pipeline consists of investigational drug candidates, and the company’s programs remain subject to clinical testing and regulatory review rather than being marketed as approved products.

Founded in 2019, Eikon is based in Hayward, California. The company was established by scientists including Nobel Prize-winning physicist Eric Betzig and has been led by Roger Perlmutter, who previously served as president of Merck Research Laboratories. Eikon’s research and development activities are focused on advancing its imaging platform and translating discoveries into potential therapies.

Key Stats

• Today's Range: $7.96 to $8.94
• 50-Day Range: $8.13 to $12.55
• 52-Week Range: $7.90 to $17.40
• Volume: 727,325 shs
• Average Volume: 592,095 shs
• Market Capitalization: $440.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Moderate Buy

Eikon Therapeutics Stock Analysis - MarketRank™

Eikon Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 257th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Eikon Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

Eikon Therapeutics has a consensus price target of $25.00, representing about 207.5% upside from its current price of $8.13.

Amount of Analyst Coverage

Eikon Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Eikon Therapeutics are expected to grow in the coming year, from ($7.24) to ($7.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eikon Therapeutics is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eikon Therapeutics is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.75% of the float of Eikon Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Eikon Therapeutics has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Eikon Therapeutics has recently increased by 26.35%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eikon Therapeutics does not currently pay a dividend.

Dividend Growth

Eikon Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.67

News Sentiment

Eikon Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Eikon Therapeutics this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for EIKN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

4 people have added Eikon Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $1,031,152.00 in company stock, which represents 0.2341% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Eikon Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,031,152.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

Eikon Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EIKN
• CIK: 1861123
• Web: www.eikontx.com
• Phone: (341) 777-0566
• Fax: N/A
• Employees: 384
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Eikon Therapeutics: $25.00
• High Price Target: $34.00
• Low Price Target: $4.00
• Potential Upside/Downside: +207.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.89
• Quick Ratio: 9.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 54,170,000
• Free Float: N/A
• Market Cap: $440.40 million
• Optionable: N/A
• Beta: N/A